Alana Brennan
Profiles

Alana T Brennan, PhD

Associate Professor , Global Health - Boston University School of Public Health

617-358-2407
abrennan@bu.edu
Crosstown Center
View Full Profile at BUMC

Biography

Alana Brennan, PhD, MPH is an Associate Professor in the Department of Global Health at the Boston University School of Public Health. She received both her MPH in Epidemiology and PhD in Epidemiology from the Boston University School of Public Health. Her areas of expertise are in HIV, tuberculosis, non-communicable chronic disease, and health systems research.

Other Positions

  • Associate Professor, Epidemiology - Boston University School of Public Health

Education

  • Boston University School of Public Health, PhD Field of Study: Epidemiology
  • Boston University School of Public Health, MPH Field of Study: Epidemiology
  • Knox College, BS Field of Study: Biology

Websites

Classes Taught

  • SPHEP755

Publications

  • Published on 1/8/2026

    Holmes J, Morris D, Gillespie D, Brennan A, Leeming G, Chen RKL, Wilson L, Angus C. Public health impacts of increasing the minimum unit price for alcohol in Scotland: A model-based appraisal. PLoS Med. 2026 Jan; 23(1):e1004792. PMID: 41505661.

     Read At: PubMed
  • Published on 1/6/2026

    Chen RKL, Morris D, Angus C, Gilmore A, Hiscock R, Holmes J, Langley TE, Pryce R, Wilson LB, Brennan A, Gillespie D. Reducing the exceptional affordability of hand-rolling tobacco using tax escalators: a health and economic impact modelling study for England. Tob Control. 2026 Jan 06. PMID: 41494920.

     Read At: PubMed
  • Published on 12/24/2025

    Kuhn L, Brennan AT. No cause for complacency regarding health of children who are HIV-exposed but uninfected. AIDS. 2026 Feb 01; 40(2):249-251. PMID: 41457985.

     Read At: PubMed
  • Published on 12/10/2025

    Sass N, Havrylenko H, Gerber F, Amstutz A, Rosen S, Brennan A, Maskew M, Koenig S, Dorvil N, Geng EH, Glass T, Ford NP, Labhardt ND, Schandelmaier S. Effect of same-day HIV treatment initiation (SDI) on 1-year outcomes in low- and middle-income countries: systematic review and meta-analysis of randomised trials. BMJ Glob Health. 2025 Dec 10; 10(12). PMID: 41371927.

     Read At: PubMed
  • Published on 12/1/2025

    Dzomba A, Shumba K, Nattey C, Lauren E, Brennan AT, McLoed W, Fox MP, Bor J, Onoya D. HIV Patient Treatment Adherence Trajectories in First 24 months After ART Initiation Among Adults: An Electronic Health Records Cohort From South Africa. J Acquir Immune Defic Syndr. 2025 Dec 01; 100(4):305-314. PMID: 40778758.

     Read At: PubMed
  • Published on 10/21/2025

    Brennan AT, Lauren E, Bor J, George JA, Khoza S, Mlisana K, Kileel EM, Rosen S, Raal F, Hibberd P, Fox MP, Crowther NJ. Gaps in the Type 1 Diabetes Mellitus care cascade: a national perspective using South Africa's National Health Laboratory Service (NHLS) database. medRxiv. 2025 Oct 21. PMID: 41040711.

     Read At: PubMed
  • Published on 9/22/2025

    Zheng A, Brennan AT, Greener R, Kileel EM, Bor J, Venter WDF, Murray EJ, Pisa PT, Goeieman B, Fox MP, Maskew M. Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation. Infect Dis (Lond). 2026 Feb; 58(2):198-208. PMID: 40982349.

     Read At: PubMed
  • Published on 9/18/2025

    Pederson AM, Buto P, Zimmerman SC, Sims KD, Murchland AR, Wang J, Glymour MM, Weuve J, Gilsanz P, Chi F, Whitmer RA, Brennan AT. Clinical modifiers of the association between type 1 diabetes and dementia incidence. medRxiv. 2025 Sep 18. PMID: 41001474.

     Read At: PubMed
  • Published on 9/1/2025

    Zheng A, Kileel EM, Brennan AT, Flynn DB, Rosen S, Fox MP. Systematic review and meta-analysis of retention and disengagement after initiation on antiretroviral therapy in low- and middle-income countries after the introduction of Universal Test and Treat policies. J Int AIDS Soc. 2025 Sep; 28(9):e70026. PMID: 40908808.

     Read At: PubMed
  • Published on 6/1/2025

    Zheng A, Fox MP, Greener R, Kileel EM, Bor J, Venter WDF, Pisa PT, Brennan AT, Maskew M. Initiation of Dolutegravir Versus Efavirenz on Viral Suppression and Retention at 6 months: A Regression Discontinuity Design. J Acquir Immune Defic Syndr. 2025 Jun 01; 99(2):151-157. PMID: 39913899.

     Read At: PubMed

View 91 more publications:View Full Profile at BUMC

News & In the Media

View all profiles